How Expert Panel Gave Nod to Bharat Biotech s Covaxin: What Minutes of Meetings Revealed
Even as Bharat Biotech last week called the restricted emergency use of its Covid-19 vaccine Covaxin ‘a great milestone for India s scientific capability’, minutes from a meeting of the subject expert committee set up by the India’s drug regulator Central Drugs Standard Control Organization show that the panel wasn’t sure of the “efficacy” of the vaccine but changed its mind within a day.
Reports suggest that the expert panel changed its mind about the vaccine in 24 hours last week. While experts had expressed apprehension, the makers of Covaxin had it out at critics calling it 200% safe .
Experts concerned as India approves two COVID-19 vaccines: What we know so far
Many experts have raised concerns over the approval of the vaccines as both developers are yet to release data on their respective phase-3 clinical trials in India.
By Hanie Abdul Razak| Updated: 6th January 2021 4:53 pm IST Covishield is developed by Serum Institute of India (SII) and Covaxin is developed by Bharat Biotech.
On Sunday, the central drugs and standards committee organization (CDSCO) approved two vaccines to fight COVID-19 Oxford-based
Covishield developed by Serum Institute of India (SII) and indigenously developed
Covaxin of Bharat Biotech for restricted emergency use in the country.
Welcome To IANS Live - NATION - AIDAN asks DCGI to withdraw approval for Bharat Biotech s Covaxin ianslive.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ianslive.in Daily Mail and Mail on Sunday newspapers.
Stage-3 Trials Given A Miss: Congress Leaders On Covid Vaccine Approval Stage-3 Trials Given A Miss: Congress Leaders On Covid Vaccine Approval Congress leader Salman Nizami went to the extent of tweeting: Vaccine is a fraud.
Updated: January 03, 2021 5:41 pm IST
A parliamentary panel had earlier recommended proper conduct of vaccine trials.
New Delhi:
The Indian government must explain why mandatory protocols and verification of data from stage-3 trials have been dispensed with while granting permission for the emergency use of the two COVID-19 vaccines, the Congress party asked today. The issue is pertinent since no other country has apparently dispensed with these key processes, the opposition party said.